Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Prim, S.A. is a Spanish company specializing in health technology, mobility, and healthcare products, with over 150 years of experience in the health industry. It provides a comprehensive range of hospital and orthopedic supplies, including collars, clavicle supports, arm slings, hand and finger orthoses, shoulder, elbow, and wrist products, as well as lower limb solutions like calf braces, thigh, hip, knee, ankle, and foot aids. The company also offers shoulder and back supports, bands, corsets, hyperextension braces, and thoracic protectors under brands such as airtex PRO, ORTHOPrim, PRIMcare, and Primespine. Prim, S.A. serves healthcare units including operating theatres, pain management centers, plastic surgery, endosurgery, and cardiovascular departments, while supporting physiotherapy, thalassotherapy, thermal therapy, rehabilitation, geriatrics, and daily living aids. Headquartered in Móstoles, Madrid, with 954 employees, it operates PrimAcademy for training and emphasizes innovation, quality, transparency, and work-life balance as a family-responsible company. Listed on the stock exchange, Prim, S.A. plays a key role in the medical instruments and supplies sector, contributing to improved health and quality of life.
€12.85
€0.20 (-1.53%)
EOD Jun 23, 2026 · Twelve Data
Operating margin is thin at 8.93%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 8.0%, steady but not accelerating.
Even for strong businesses, today's 13x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
13.1x earnings, 12.1x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€252M
▲ +8.0% YoY
Net Income (TTM)
€17M
▲ +52.8% YoY
Op. Margin
8.93%
▲ +2.2pp YoY
ROIC
11.40%
▲ +3.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€18M
▲ +68.6% YoY
Op. Cash Flow (TTM)
€30M
▲ +38.1% YoY
Net Debt
-€8M
Net Cash Position
Cash & Equiv.
€23M
3Y CAGR: +8.5%
Continue Research